Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Introducing OXcan

OXcan, short for Oxford Cancer Analytics, uses machine learning techniques combined with cutting-edge liquid biopsy techniques, searching for stage one lung cancer biomarkers.

Introducing Evolvere Biosciences

A platform to develop biologic therapeutics that outsmart the evolution of antibiotic resistance to save millions of lives.

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

Ochre Bio announces the launch of its ‘Liver ICU’ in New York City, a world first for human liver research.

Nucleome Therapeutics Shortlisted as Finalists for the 2022 Oxfordshire Business Awards

Nucleome Therapeutics, a biotechnology company decoding the dark matter of the human genome to uncover novel ways to treat disease with precision medicines, is in the running to receive the Oxfordshire LEP New Business Award.

Exogene Raises $2M (£1.5M) for its AI Platform to Discover Cell Therapies for Cancer

The money will be used to develop its artificial intelligence (AI) platform for T-cell receptor discovery.

Kyttaro Announces Worldwide Exclusive Licensing Agreement with Lilly for Antibody Therapeutic Program

The company plans to develop Lilly’s first-in-class clinical stage anti-angiopoietin-like 3/8 monoclonal antibody for the treatment of atherosclerotic cardiovascular disease and potentially other conditions.

BioEscalator Sponsors Oxford Catalyse Programme 2022

The BioEscalator is sponsoring a prize for the Biohackaton 2022, where teams created during the Oxford Catalyse 2022 programme will pitch their final business plans to a panel of judges.

BioEscalator Opens New Laboratory

In December 2021, the BioEscalator opened a brand-new 137m2 laboratory, providing much-needed additional incubator space for Oxford-based start-ups.

Introducing Alethiomics

Alethiomics Ltd is a pre-clinical biotech company harnessing the power of single cell multiomic technology to discover and develop life-changing treatments for patients with blood cancer.

SIGA Announces Preclinical Oncology Research Collaboration with Bioarchitech

The research collaboration will investigate TPOXX® (tecovirimat) in combination with Bioarchitech’s proprietary vaccinia-based immunotherapy platform in preclinical studies.

Kyttaro Announces an Exclusive Worldwide Licensing Agreement with Oxford University Innovation

Kyttaro plans to develop a peptide technology platform to create novel biologic therapeutics addressing various causes of inflammation, a major mechanism underlying cardiovascular disease.

Ochre Bio Enters into Charitable Donation Agreement with British Liver Trust

The two companies share the same goals, to improve the lives of those dealing with liver disease.

Exact Sciences Innovation Graduates to The Oxford Science Park

Helping people get the answers they need to make more informed decisions across the cancer continuum.

Introducing CyanoCapture

CyanoCapture aims for scalable, low-cost, biological carbon capture using genetically-modified algae, known as cyanobacteria.

Gene Linked to Doubling the Risk of Death due to COVID-19 Identified Using Technology Exclusively Licensed to Nucleome Therapeutics

The technology used to identify this gene has been exclusively licensed to Nucleome, highlighting the competitive advantage of Nucleome’s platform in the discovery of genetic targets for innovative precision medicine development.

Exogene Selected for KQ Labs Accelerator Programme

Exogene has been selected as one of ten innovative startup companies, working at the interface of biomedical and data science, to receive personalised mentoring and coaching as part of the KQ Labs accelerator programme.

Introducing Kyttaro

Kyttaro is developing innovative therapeutics to treat hypertriglyceridemia, atherosclerotic cardiovascular disease and inflammatory and neurogastroenterology conditions.

Ochre Bio Shortlisted as an OBN Awards 2021 Finalist in the BioSeed ‘One to Watch’ Category

Recipients of the OBN Awards are considered to have made an outstanding and valuable contribution to their field, which is why Ochre Bio is thrilled to have made the cut at this early stage of its life.

Oxford BioEscalator Celebrates Three Years of Innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.

BioEscalator Companies Attract Record Funding as Investors Switch-on to Biotech

Despite the disruption caused by the pandemic, BioEscalator companies attracted a record high of £1.2B investment. This is part of a trend that saw investors attracted to the resilience displayed by the life science industry to the pandemic relative to other sectors.

Load More